# International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia

> **NCT03705507** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Birmingham** · enrollment: 12 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia, Adult
- Acute Lymphoblastic Leukemia, Pediatric
- Acute Lymphoblastic Leukemia, in Relapse
- Acute Lymphoblastic Leukemia Recurrent

## Interventions

- **DRUG:** Selumetinib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT03705507
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-18
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-05-03
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Poor recruitment, due to a change in the standard of care for this patient population with the use of CAR-T cells
- **Last updated:** 2023-05-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03705507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03705507, "International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic Leukaemia". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03705507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*